+ Follow OTSUKA PHARMACEUTICAL CO Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 816730
[Title] => Efficacy results of Otsuka's delamanid for MDR-TB published in journal
[Summary] => An investigational compound for the treatment of multidrug-resistant tuberculosis (MDR-TB) was shown to be effective with a good safety profile in research spearheaded by global healthcare company Otsuka Pharmaceutical Co. Ltd. (Otsuka).
[DatePublished] => 2012-06-14 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 63596
[Title] => Study Shows: Generic anti-platelet agent not bioequivalent to innovator drug
[Summary] =>
[DatePublished] => 2008-05-22 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
OTSUKA PHARMACEUTICAL CO
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 816730
[Title] => Efficacy results of Otsuka's delamanid for MDR-TB published in journal
[Summary] => An investigational compound for the treatment of multidrug-resistant tuberculosis (MDR-TB) was shown to be effective with a good safety profile in research spearheaded by global healthcare company Otsuka Pharmaceutical Co. Ltd. (Otsuka).
[DatePublished] => 2012-06-14 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 63596
[Title] => Study Shows: Generic anti-platelet agent not bioequivalent to innovator drug
[Summary] =>
[DatePublished] => 2008-05-22 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest
